# Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma

> **NCT01247623** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oslo University Hospital**

## Conditions studied

- Malignant Melanoma

## Interventions

- **BIOLOGICAL:** GV1001

## Key facts

- **NCT ID:** NCT01247623
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2011-09
- **Final completion:** 2012-09
- **Target enrollment:** — (—)
- **Last updated:** 2014-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01247623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01247623, "Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01247623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*